Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.57 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.57 |
| ▸ | TGM2 | P21980 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.51 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | TDO2 | P48775 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25335238 | 0.91 | HTT (0.67) | LMNASMN1; SMN2HTTKEAP1NFE2L2 | |
| SCHEMBL14697661 | 0.90 | HTT (0.65) | LMNASMN1; SMN2HTTKEAP1NFE2L2 | |
| SCHEMBL5286719 | 0.88 | TGM2 (0.64) | LMNASMN1; SMN2HTTKEAP1NFE2L2 | |
| SCHEMBL16515771 | 0.87 | HTT (0.58) | LMNASMN1; SMN2HTTKEAP1NFE2L2 | |
| SCHEMBL6539554 | 0.86 | LMNA (0.67) | LMNASMN1; SMN2HTTKEAP1NFE2L2 | |
| SCHEMBL17243743 | 0.85 | HTT (0.63) | LMNASMN1; SMN2HTTKEAP1NFE2L2 | |
| SCHEMBL13055383 | 0.85 | LMNA (0.80) | LMNASMN1; SMN2HTTKEAP1NFE2L2 | |
| SCHEMBL2391033 | 0.84 | LMNA (0.65) | LMNASMN1; SMN2HTTKEAP1NFE2L2 | |
| SCHEMBL3211861 | 0.84 | LMNA (0.59) | LMNASMN1; SMN2HTTKEAP1NFE2L2 | |
| SCHEMBL18254066 | 0.82 | HTT (0.81) | LMNASMN1; SMN2HTTKEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731622-A1 | COMPOUNDS AND COMPOSITIONS AS VHL LIGANDS AND STAT3 DEGRADERS USES THEREOF | Regents of the University of Michigan (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260108613-A1 | Compounds and Compositions as VHL Ligands and STAT3 Degraders Uses Thereof | UNIV MICHIGAN (US) | 2026-04-23 | — | — | US | disclosed |
| US-20250109110-A1 | BICYCLIC-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2025-04-03 | — | — | US | disclosed |
| WO-2024263673-A1 | COMPOUNDS AND COMPOSITIONS AS VHL LIGANDS AND STAT3 DEGRADERS USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2023146896-A1 | BICYCLIC-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-11584759-B2 | Macrocyclic kinase inhibitor | HITGEN INC. (CN) | 2023-02-21 | — | — | US | disclosed |
| EP-3783000-B1 | MACROCYCLIC KINASE INHIBITOR | HITGEN INC (CN) | 2022-07-06 | — | — | EP | disclosed |
| US-20210147443-A1 | MACROCYCLIC KINASE INHIBITOR | HITGEN INC. (CN) | 2021-05-20 | — | — | US | disclosed |
| EP-3783000-A1 | MACROCYCLIC KINASE INHIBITOR | Hitgen Inc. (CN) | 2021-02-24 | — | — | EP | disclosed |
| US-20190308943-A1 | 3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS | PARION SCIENCES, INC. (US) | 2019-10-10 | — | — | US | disclosed |
| WO-2007146869-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | PARION SCIENCES, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| EP-1786426-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | Parion Sciences, Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20070021439-A1 | Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021439-A1 | Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20060142581-A1 | Hetero substitued sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| EP-1599096-A4 | HETERO SUBSTITUED SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2006022935-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060040954-A1 | Soluble amide & ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-02-23 | — | — | US | disclosed |
| EP-1599096-A2 | HETERO SUBSTITUED SODIUM CHANNEL BLOCKERS | Parion Sciences, Inc. (US) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004073629-A2 | HETERO SUBSTITUED SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142581-A1 | Hetero substitued sodium channel blockers | SCN2B, CACNA1B, CACNA1G | LMNA 3223/4885SMN1; SMN2 1868/4885HTT 618/4885 |
| US-20260108613-A1 | Compounds and Compositions as VHL Ligands and STAT3 Degraders Uses Thereof | VHL, NCOR1, NCOR2 | LMNA 3145/4885SMN1; SMN2 2677/4885HTT 1039/4885 |
| US-20210147443-A1 | MACROCYCLIC KINASE INHIBITOR | MAP3K20, TNK2, NTRK1 | LMNA 3853/4885SMN1; SMN2 1556/4885HTT 2815/4885 |
| US-20190308943-A1 | 3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS | CFTR, SCNN1B, SCN5A | LMNA 1942/4885SMN1; SMN2 3597/4885HTT 4494/4885 |
| US-20060040954-A1 | Soluble amide & ester pyrazinoylguanidine sodium channel blockers | SCN2A, CACNA1B, HCN4 | LMNA 1935/4885SMN1; SMN2 1611/4885HTT 1711/4885 |
| US-20070021439-A1 | Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers | KCNN2, KCNN1, KCNN3 | LMNA 1058/4885SMN1; SMN2 2287/4885HTT 2675/4885 |
| US-11584759-B2 | Macrocyclic kinase inhibitor | MAP3K20, TNK2, NTRK1 | LMNA 3853/4885SMN1; SMN2 1556/4885HTT 2815/4885 |
| US-20250109110-A1 | BICYCLIC-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1A | LMNA 1512/4885SMN1; SMN2 1854/4885HTT 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.